ENGN NASDAQ
enGene Holdings Inc.
1W: +0.0%
1M: -19.4%
3M: -10.2%
YTD: -82.2%
1Y: -79.9%
$1.55
-0.03 (-1.90%)
After Hours: $1.69 (+0.14, +8.71%)
Weekly Expected Move ±8.1%
$1
$1
$2
$2
$2
Credit Risk of going bust: higher than 96% of companies Debt: 23.9% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.14 (down 91%), enGene Holdings Inc. would be worth roughly what it owes.
Total debt $33.3M against a stock market value of $105.9M.
Distance to default 0.41 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $15.0M (short-term plus half of long-term), stock volatility 182.9%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $33.3M against a stock market value of $105.9M.
Distance to default 0.41 (Merton model): prices to 2026-10-26, balance sheet 2026-07-31, debt counted $15.0M (short-term plus half of long-term), stock volatility 182.9%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$103.9M
52W Range1.4-12.25
Volume344,133
Avg Volume834,114
Beta-0.28
Dividend—
Analyst Ratings
Company Info
CEORonald H. W. Cooper
Employees82
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
4868 Rue Levy
Montreal, QC H4R 2P1
CA
Montreal, QC H4R 2P1
CA
514 332 4888
About enGene Holdings Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Latest News
enGene Holdings GAAP EPS of -$0.47 misses by $0.04
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Recommendation of “Hold” by Brokerages
enGene (NASDAQ:ENGNW) Shares Up 5% – Should You Buy?
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Grossman William | P-Purchase | 5,102 | $1.97 | 2026-09-22 |
| Chinoporos Constanti | 75,000 | $1.75 | 2026-07-16 | |
| Richton Kathleen P. | 0 | — | 2026-07-16 | |
| Richton Kathleen P. | 45,000 | $7.39 | 2026-07-16 | |
| Richton Kathleen P. | 13,900 | $9.53 | 2026-07-16 |